Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma

Cancer Research

Volumn 63, Issue 10, 2003, Pages 2447-2453

  Rosanò, Laura ^a   Spinella, Francesca ^a   Salani, Debora ^a   Di Castro, Valeriana ^a   Venuti, Aldo ^a   Nicotra, Maria Rita ^b   Natali, Pier Giorgio ^a   Bagnato, Anna ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATRASENTAN; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; GELATINASE A; PACLITAXEL; TAXANE DERIVATIVE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL DIVISION; DRUG SYNERGISM; ENDOTHELIAL GROWTH FACTORS; FEMALE; GROWTH INHIBITORS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PACLITAXEL; PYRROLIDINES; RECEPTOR, ENDOTHELIN A; RECEPTORS, ENDOTHELIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037843596     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Ozols, R. F. Paclitaxel plus carboplatin in the treatment of ovarian cancer. Semin. Oncol., 26: 84-89, 1999.
2. Greenlee, R. T., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 2000. CA Cancer J. Clin., 50: 7-33, 2000.
3. Nelson, J. B., Hedican, S. P., George, D. J., Reddi, A. H., Piantadosi, S., Eisenberger, M. A., and Simons J. W. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med., 1: 994-999, 1995.
4. Gohji, K., Kitazawa, S., Tamada, H., Katsuoka, Y., and Nakajima, M. Expression of endothelin receptor A associated with prostate cancer progression. J. Urol., 165: 1033-1036, 2001.
5. Bagnato, A., Salani, D., Di Castro, V., Wu-Wong, J. R., Tecce, R., Nicotra, M. R., Venuti, A., and Natali, P. G. Expression of endothelin-1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res., 59: 720-727, 1999.
6. Egidy, G., Juillerat-Jeanneret, L., Jeannin, J. F., Korth, P., Bosman, F. T., and Pinet, F. Modulation of human colon tumor-stromal interactions by endothelin system. Am. J. Pathol., 157: 1863-1874, 2000.
7. Venuti, A., Salani, D., Manni, V., Poggiali, F., and Bagnato, A. Expression of endothelin-1 and endothelin A receptor in HPV-associated cervical carcinoma: new potential targets for anticancer therapy. FASEB J., 14: 2277-2283, 2000.
8. Baley, P. A., Resink, T. J., Eppenberger, U., and Hahn, A. W. Endothelin messenger RNA and receptors are differentially expressed in cultured human breast epithelial and stromal cells. J. Clin. Invest., 85: 1320-1323, 1990.
9. Economos, K., MacDonald, P. C., and Casey, M. L. Endothelin-1 gene expression and biosynthesis in human endometrial HEC-1A cancer cells. Cancer Res., 52: 554-557, 1992.
10. Lahav, R., Heffner, G., and Patterson, P. H. An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. Proc. Natl. Acad. Sci. USA, 96: 11496-11500, 1999.
11. Bagnato, A., Rosanò, L., Di Castro, V., Albini, A., Salani, D., Varmi, M., Nicotra, M. R., and Natali, P. G. Endothelin receptor blockade inhibits proliferation of Kaposi's sarcoma cells. Am. J. Pathol., 158: 841-847, 2001.
12. Rubanyi, G. M., and Polokoff, M. A. Endothelins: molecular biology, biochemistry, pharmacology, physiology and pathophysiology. Pharmacol. Rev., 46: 325-415, 1994.
13. Bagnato, A., Tecce, R., Di Castro, V., and Catt, K. J. Activation of mitogenic signaling by endothelin-1 in ovarian carcinoma cells. Cancer Res., 57: 1306-1311, 1997.
14. Bagnato, A., and Catt, K. J. Endothelins as autocrine regulators of tumor cell growth. Trends Endocrinol. Metab., 9: 378-383, 1998.
15. Bagnato, A., Tecce, R., Moretti, C., Di Castro, V., Spergel, D. J., and Catt, K. J. Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cells. Clin. Cancer Res., 1: 1059-1066, 1995.
16. Vacca, F., Bagnato, A., Catt, K. J., and Tecce, R. Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res., 60: 5310-5317, 2000.
17. Alvarez, A. A., Krigman, H. R., Whitaker, R. S., Dodge, R. K., and Rodriguez, G. C. The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin. Cancer Res., 5: 587-591, 1999.
18. Zebrowski, B. K., Liu, W., Ramirez, K., Akagi, Y., Mills, G. B., and Ellis, L. M. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann. Surg. Oncol., 6: 373-378, 1999.
19. Salani, D., Di Castro, V., Nicotra, M. R., Rosanò, L., Tecce, R., Venuti, A., Natali, P. G., and Bagnato, A. Role of endothelin-1 in neovascularization of ovarian carcinoma. Am. J. Pathol., 157: 1537-1547, 2000.
20. Salani, D., Taraboletti, G., Rosanò, L., Di Castro, V., Borsotti, P., Giavazzi, R., and Bagnato, A. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am. J. Pathol., 157: 1703-1711, 2000.
21. Cruz, A., Pamot, C., Ribatti, D., Corvol, P., and Gasc, J. M. Endothelin-1, a regulator of angiogenesis in the chick chorioallantoic membrane. J. Vasc. Res., 38: 536-545, 2001.
22. Spinella, S, Rosanò, L., Di Castro, V., Natali, P. G., and Bagnato, A. Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1α in ovarian carcinoma cells. J. Biol. Chem., 277: 27850-27855, 2002.
23. Rosanò, L., Varmi, M., Salani, D., Di Castro, V., Spinella, F., Natali, P. G., and Bagnato, A. Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res., 61: 8340-8346, 2001.
24. Wu-Wong, J. R., Chiou, W. J., Dickinson, R., and Opgenorth, T. J. Endothelin attenuates apoptosis in human smooth muscle cells. Biochem. J., 328: 733-737, 1997.
25. Eberl, L. P., Valdenaire, O., Saintgiorgio, V., Jeannin, J. F., and Juillerat-Jeanneret, L. Endothelin receptor blockade potentiates fasL-induced apoptosis in rat colon carcinoma cells. Int. J. Cancer, 86: 182-187, 2000.
26. Del Bufalo, D., Di Castro, V., Biroccio, A., Varmi, M., Salani, D., Rosanò, L., Trisciuoglio, D., Spinella, F., and Bagnato, A. Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for AKT activation. Mol. Pharmacol., 61: 524-532, 2002.
27. Pirtskhalaishvili, G., and Nelson, J. B. The endothelin receptor: a novel target for anticancer therapy. Am. J. Cancer, 1: 1-7, 2002.
28. Verhaar, M. C., Grahn, A. Y., Van Weerdt, A. W., Honing, M. L., Morrison, P. J., Yang, Y. P., Padley, R. J., and Rabelink, T. J. Pharmacokinetics and pharmaeodynamic effects of ABT-627, an oral ETA selective endothelin antagonist, in humans. Br. J. Clin. Pharmacol., 49: 562-573, 2000.
29. Tortora, G., Caputo, R., Damiano, V., Bianco, R., Pepe, S., Bianco, A. R., Jiang, Z., Agrawal, S., and Ciardiello, F. Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A. Proc. Natl. Acad. Sci. USA. 94: 12586-12591, 1997.
30. Ciardiello, F., and Tortora, G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res., 7: 2958-2970, 2001.
31. Tsao, S. W., Mok, S. C., Fey, E. G., Fletcher, J. A., Wan, T. S., Chew, E. C., Muto, M. G., Knapp, R. C., and Berkowitz, R. S. Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). Exp. Cell Res., 218: 499-507, 1995.
32. Buick, R. N., Pullano, R., and Trent, J. M. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res., 45: 3668-3676, 1985.
33. Weidner, N., Sample, J. P., Welch, W. R., and Folkman, J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med., 324: 1-8, 1991.
34. Salani, D., Rosanò, L., Di Castro, V., Spinella, F., Venuti, A., Padley, R. J., Nicotra, M. R., Natali P. G., and Bagnato, A. ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma growth in vitro. Clin. Sci., 103: 318S-321S, 2002.
35. Venuti, A., Salani, D., Cirilli, A., Simeone, P., Muller, A., Flamini, S., Padley, R., and Bagnato A. Endothelin receptor blockade inhibits the growth of human papillomavirus-associated cervical carcinoma. Clin. Sci., 103: 310S-313S, 2002.
36. Belotti, D., Vergani, V., Drudis, T., Borsotti, P., Pitelli, M. R., Viale, G., Giavazzi, R., and Taraboletti, G. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res., 2: 1843-1849, 1996.
37. Nelson, J., Bagnato, A., Battistini, B., and Nisen, P. The endothelin axis: emerging role in cancer. Nat. Rev. Cancer, 3: 110-116, 2003.
38. Ryan, H. E., Poloni, M., McNulty, W., Elson, D., Gassmann, M., Arbeit, J. M., and Johnson, R. S. Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Cancer Res., 60: 4010-4015, 2000.
39. Birner, P., Schindl, M., Obermair, A., Breitenecker, G., and Oberhuber, G. Expression of hypoxia-inducible factor 1 α in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin. Cancer Res., 7: 1661-1668, 2001.
40. Stack, M. S., Ellerbrock, S. M., and Fishman, D. A. The role of proteolytic enzyme in the pathology of epithelial ovarian carcinoma. Int. J. Oncol., 12: 569-576, 1998.
41. Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med., 6: 389-395, 2000.
42. Sood, A. K., Septor, E. A., Fletcher, M. S., Gardner, L. M. G., Heidger, P. M., Buller, R. E., Septor, R. E. B., and Hendrix, M. J. C. Molecular determinants of ovarian cancer plasticity. Am. J. Pathol., 158: 1279-1288, 2001.
43. Shirakawa, K., Kobayashi, H., Heike, Y., Kawamoto, S., Brechbiel, M. B., Kasumi, F., Iwanaga, T., Konishi, F., Terada, M., and Wakasugi, H. Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Res., 62: 560-566, 2002.
44. Seftor, R. E., Seftor, E. A., Koshikawa, N., Meltzer, P. S., Gardner, L. M., Bilban, M., Stetler-Stevenson, W. G., Quaranta, V., and Hendrix, M. J. Cooperative interactions of laminin 5γ2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res., 61: 6322-6327, 2001.
45. Bagnato, A., and Spinella, F. Emerging role of endothelin-1 in tumor angiogenesis. Trends Endocrinol. Metab., 14: 44-50, 2002.
46. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell, 78: 539-542, 1994.
47. Carducci, M. A., Nelson, J. B., Bowling, M. K., Rogers, T., Eisenberger, M. A., Sinibaldi, V., Donehower, R., Leahy, T. L., Carr, R. A., Isaacson, J. D., Janus, T. J., Andre, A., Hosmane, B. S., and Padley, R. J. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J. Clin. Oncol., 20: 2171-2180, 2002.
48. Van der Boon, J. New drug slows prostate-cancer progression. Lancet Oncol., 3: 201, 2000.
49. Carducci, M. A., Padley, R. J., Breul, J., Vogelzang, N. J., Zonnenberg, B. A., Daliani, D. D., Schulman, C. C., Nabulsi, A. A., Humerickhouse, R. A., Weinberg, M. A., Schmitt, J. L., and Nelson, J. B. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized. Phase II, placebo-controlled trial. J. Clin. Oncol., 21: 679-689, 2003.
50. Bagnato, A., Cirilli, A., Salani, D., Simeone, P., Muller, A., Nicotra, M. R., Natali, P. G., and Venuti, A. Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade. Cancer Res., 62: 638-6384, 2002.